Last updated on September 2017

INCB 18424-272 A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who are Resistant to or Intolerant of Hydroxyurea


Brief description of study

INCB 18424-272 A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who are Resistant to or Intolerant of Hydroxyurea

Detailed Study Description

Ruxolitinib (previously known as INCB018424 phosphate, INC424, ruxolitinib phosphate) is a novel, potent, and selective inhibitor of Janus kinase (JAK) 1 and JAK2 with modest to marked selectivity against tyrosine kinase 2 (TYK2) and JAK3, respectively. Ruxolitinib has been granted marketing authorisation approval for the treatment of myelofibrosis (MF) and polycythemia vera (PV) and is currently in development for the treatment of myeloproliferative neoplasms (MPNs; MF, PV, and essential thrombocythemia [ET]) and other hematologic malignancies.

Clinical Study Identifier: TX153063

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.